Synapse - Raajit Rampal

Results (338)

TP53 alterations confer increased risk of leukemic transformation and worse survival as compared to high molecular risk mutations in patients with myeloproliferative neoplasms

Meeting Abstract

Handa, S.; Riazat-Kesh, Y. J. R. A.; Butterfield, R. J.; Sivakumar, G.; Venugopal, S.; McGovern, E.; Feld, J.; Tremblay, D.; Elghaity-Beckley, S.; Kremyanskaya, M.; more...
Blood (2024)

Fulltext@MSK | Save

A multicenter, open-label, phase 1 clinical trial of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a type I JAK2 inhibitor (JAK2i)

Meeting Abstract

Mascarenhas, J. O.; Borate, U.; Bose, P.; Byrd, J. C.; Garcia, J. S.; Grunwald, M. R.; Hobbs, G. S.; Hoffman, R.; Kuykendall, A. T.; Mesa, R. A.; more...
Blood (2024)

Fulltext@MSK | Save

POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib

Meeting Abstract

Vachhani, P.; Rampal, R.; Bradley, T.; Harrison, C.; Jain, T.; Kuykendall, A. T.; Palandri, F.; Mascarenhas, J. O.; Al-Ali, H. K.; Passamonti, F.; more...
Blood (2024)

Fulltext@MSK | Save

Trial in progress: An open-label clinical trial of RVU120 as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)

Meeting Abstract

Kuklik, R.; Falkowski, A.; Zaroogian, Z.; Mazan, M.; Szymula, A.; Wilkinson, G.; Adamczyk, E.; Woznicki, J.; Micek, M.; Coelho, D.; more...
Blood (2024)

Fulltext@MSK | Save

Early anemia response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Meeting Abstract

Mascarenhas, J. O.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.
Blood (2024)

Fulltext@MSK | Save

Real-word effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Meeting Abstract

Rampal, R.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Mascarenhas, J. O.
Blood (2024)

Fulltext@MSK | Save

A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis

Meeting Abstract

Mascarenhas, J. O.; Rampal, R.; El Chaer, F.; Gupta, V.; Shimoda, K.; Kiladjian, J. J.; Passamonti, F.; Bose, P.; Scandura, J. M.; Mesa, R.; more...
Blood (2024)

Fulltext@MSK | Save

Improvement in serum albumin as a measure of improved metabolic profile in pacritinib-treated patients: A retrospective analysis of patients treated across three clinical trials

Meeting Abstract

Palandri, F.; Sobas, M.; Harrison, C.; Rampal, R.; Buckley, S.; Suthar, P.; Roman-Torres, K.; Mascarenhas, J. O.
Blood (2024)

Fulltext@MSK | Save

Cytokine modulation correlates strongly with symptom improvement in patients with myelofibrosis treated with nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor

Meeting Abstract

Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; Rampal, R.; Scandura, J. M.; Takami, A.; McCloskey, J.; Ichii, M.; Shirane, S.; more...
Blood (2024)

Fulltext@MSK | Save

Updated results from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis

Meeting Abstract

Mascarenhas, J. O.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
Blood (2024)

Fulltext@MSK | Save

Raajit Kumar Rampal

Results (338)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract